Search Results

Sol-Gel Technologies, Ltd. today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.

Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”) today announced that it has begun Phase 3 testing of SGT-610 (patidegib gel, 2%) for Gorlin syndrome with the first patient screened.

Sol-Gel Technologies, Ltd. announced that it received a notification letter on May 21 2024, from the Nasdaq Stock Market LLC Listing Qualifications Department, stating that the Company is not in compliance with the requirement to maintain a minimum bid price of $1 per share, as set forth in Rule 5450 of the Nasdaq Listing Rules, since the closing bid price for the Company’s ordinary Shares listed on Nasdaq was below US$1.00 for 33 consecutive business days.

Sol-Gel Technologies, Ltd. announced that Padagis Israel Pharmaceuticals Ltd, Sol-Gel’s collaboration partner, submitted a first-to-file Abbreviated New Drug Application to the U.S. Food and Drug Administration for Roflumilast Cream, 0.3%, a drug product generic to Zoryve® Cream, indicated for the treatment of plaque psoriasis in patients six years of age and older.